MyoKardia Finds $46M For Treating Genetic Heart Disease
South San Francisco-based MyoKardia, which is developing treatments for genetics-related heart disease, said yesterday that it has raised $46M in a Series B funding. The funding came from an un-named public investment fund, Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences, an affiliate of Cowen Group, and BridgeBio LLC, along with others. MyoKardia, which is led by Tassos Gianakakos, is developing treatments for hypertrophic and dilated cardiomyopathies (HCM and DCM).
posted on Friday, May 1, 2015 (Link to more information)
Related companies:
MyoKardia Inc
Related stories:
> MyoKardia Gets $38M For Heart Disease Treatment
> EBR Systems Raises $50M For Wireless Heart Failure Treatment System
> OptiMedica Gets $25M
> Neuraltus Pharmaceuticals Finds $17M
> Protagonist Therapeutics Gains $40M
silicontap.com Home